Lack of mental health treatment available for HIV patients in the UK
March 6, 2020Medical Communications AIDS, HIV, HIV AIDS, HIV treatment, HIV/AIDS
A cross-party group of MPs have said that those with HIV do not have access to adequate mental health treatment. …
Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer
March 6, 2020Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …
Indian regulators approve first drug for patients with NASH
March 6, 2020Medical Communications FDA Approval, India, Indian Pharma, drug approval
The Drug Controller General of India (DCGI) has approved the marketing application for Zydus Cadila’s saroglitazar to treat patients with …
New study calculates median drug development costs at circa $1 billion
March 5, 2020Manufacturing and Production, Research and Development, Sales and Marketing drug development, drug prices, pharma
New research has pinned a concrete figure on the perennial industry question: how much does it cost to bring a …
UK cases of coronavirus hit 90 as health officials move into next phase of their response
March 5, 2020Business Services Chinese Coronavirus, MERS, Sars, Wuhan Coronavirus, coronavirus
The coronavirus has continued to spread across the UK as health officials announce they have moved into the second stage …
China approves Roche’s Actemra to fight severe complications stemming from coronavirus
March 5, 2020Sales and Marketing Actemra, China, Roche, coronavirus, pharma
China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in …
Researchers have tested CRISPR gene editing inside a person’s body for the first time
March 5, 2020Business Services Editas, crispr, gene editing
Allergan and Editas Medicine have treated their first patient in a clinical trial with CRISPR gene editing. This therapy is …
US prescription drug net costs rose three times faster than inflation from 2007 to 2018
March 5, 2020Business Services Big Pharma, Trump drug prices, US Drug prices, drug prices, us drugs
The nest cost of prescription drugs rose over three times faster than the rate of inflation over the course of …
Positive CHMP approval for Takeda’s Alunbrig in ALK+ advanced non-small lung cancer
March 4, 2020Research and Development CHMP, EMA, Takeda, lung cancer, pharma
Takeda’s Alunbrig (brigatinib) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
Big Pharma more profitable than most public firms
March 4, 2020Research and Development Big Pharma, US Pharma, drug prices, drug regulations, regulations
Large pharmaceutical companies make a much larger profit than most other public companies, according to a new study. The research …
India reducing API exports due to coronavirus threatening global supply chain
March 4, 2020Research and Development APIs, Active Pharmaceuticals Ingredients, Big Pharma, Chinese Coronavirus, Wuhan Coronavirus, coronavirus
India is set to reduce exports of active pharmaceutical ingredients (APIs) until further notice, due to fears of internal drug …
NICE recommends avatrombopag to treat thrombocytopenia in chronic liver disease
March 4, 2020Research and Development Avatrombopag, NHS, NICE, UK, chronic liver disease
UK drug watchdog NICE has announced its final draft guidance recommending avatrombopag for routine use on the NHS in England …
Trump meets pharmaceutical executives to discuss COVID-19 vaccine
March 4, 2020Research and Development COVID-19, Chinese Coronavirus, Trump, Wuhan Coronavirus, coronavirus
President Trump has met with several representatives of the top pharmaceutical companies to discuss progress being made on a coronavirus …
MSD’s Phase 3 study of lymphoma treatment meets primary endpoints
March 3, 2020Manufacturing and Production B-cell lymphoma, classical Hodgkin Lymphoma, lymphoma
MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical …
Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma
Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …
Novartis’ subsidiary Sandoz agrees to pay $195 million to settle antitrust case
March 3, 2020Manufacturing and Production Novartis, US Courts, generic drugs, generics, price fixing, price-fixing
Novartis’ Sandoz will pay a $195 million criminal penalty to resolve charges that it conspired to price-fix, rig bids and …
Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma
Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …
99% of Doctors feel NHS is not ready to deal with coronavirus, new survey finds
March 3, 2020Manufacturing and Production Boris, Chinese Coronavirus, UK Coronavirus, Wuhan Coronavirus, coronavirus
Most NHS doctors, that partcipated in a survey, feel the organization is not well prepared to deal with a major …
Funding overview for the pharmaceutical industry and outlook for 2020
March 2, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020, M&A, MA, feature, mergers & acquisitions, opinion, pharma
This article was originally published in the January/February 2020 issue of Pharmafocus.With the advent of a New Year, Michael Jewell, …
GW Pharma takes back control of UK Sativex sales from Bayer
March 2, 2020Sales and Marketing Bayer, GW Pharma, Sativex, UK
British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
